The primary objective of this clinical trial is to determine if treatment with ubiquinol, a
form of coenzyme Q10, improves the physical function of men and women Veterans suffering from
Gulf War Illness (GWI). The primary outcome measure is a change from baseline on the Short
Form Health Survey 36-item (SF-36), with respect to physical functioning and symptoms.
Secondary outcome measures include changes from baseline levels on GWI-associated biomarkers
in peripheral blood and GWI-associated symptoms of chronic pain, fatigue, insomnia, activity
level, and cognitive and mental functioning.